We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

BioAlliance Pharma to Continue its Phase III Clinical Trial with Livatag®

News   May 14, 2013

 
BioAlliance Pharma to Continue its Phase III Clinical Trial with Livatag®
 
 
 

RELATED ARTICLES

5.1 Million Dollar Funding Boost for Blinding Retinal Conditions

News

A $5.1 million grant has been awarded from the California Institute for Regenerative Medicine to advance the development of a novel therapy for blinding retinal conditions.

READ MORE

Immunotherapy Success for Triple-Negative Breast Cancer

News

New research has shown that by using a combination of immunotherapy and chemotherapy the body’s own immune system can be tuned to attack triple-negative breast cancer, extending survival by up to ten months.

READ MORE

Proactive Approach Protects Population From HIV

News

A preventative approach to HIV drastically reduced the number of HIV diagnoses in New South Wales, Australia.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE